Get the Daily Brief
Latest Biotech News
Breakthrough Antibody–Bottlebrush Prodrugs Expand Cancer Therapeutics
Researchers unveiled antibody–bottlebrush prodrug conjugates that overcome payload potency and stability limitations of conventional antibody–drug conjugates (ADCs). This modular synthesis allows...
Imperial Scientists Uncover ‘Microbial Piracy’ Mechanism to Combat Drug Resistance
A team at Imperial College London discovered that phage satellites hijack tails from unrelated bacteriophages, forming hybrid viruses that facilitate genetic exchange among bacteria. This...
Medicus Pharma Acquires Antev, Tapping $6 Billion Prostate Cancer Market
Medicus Pharma completed acquisition of UK-based Antev Limited, gaining full rights to Teverelix, a GnRH antagonist targeting prostate cancer and acute urinary retention. Valued at an estimated $6...
NRG Therapeutics Raises $67 Million to Test Mitochondrial Treatments for ALS
NRG Therapeutics Ltd., focused on neuroscience, secured a £50 million (approximately $67 million) Series B funding to advance preclinical development of novel small molecules modulating the...
Novartis Accelerates Cardiovascular Pipeline with $1.4B Tourmaline Acquisition
Novartis has completed a $1.4 billion acquisition of Tourmaline Bio, securing rights to pacibekitug, an anti-IL-6 monoclonal antibody aimed at atherosclerotic cardiovascular disease (ASCVD)....
Rapport Therapeutics’ Seizure Drug RAP-219 Shakes Up Epilepsy Market
Rapport Therapeutics reported striking Phase IIa results for its focal onset seizure drug RAP-219, showing a 78% median reduction in clinical seizures over eight weeks. The open-label study,...
WCLC 2025: Emerging Small Cell Lung Cancer Therapies Reveal Mixed Outcomes
At the World Conference on Lung Cancer (WCLC) 2025, several investigational treatments for small cell lung cancer (SCLC) showed promising yet mixed clinical trial results. BioNTech and Bristol...
FDA Returns Complete Response Letter for Saol’s Rare Genetic Disorder Treatment
Saol Therapeutics received an FDA complete response letter (CRL) for its NDA on sodium dichloroacetate (SL-1009), an experimental drug for pyruvate dehydrogenase complex deficiency, a rare...
AI-Driven Drug Discovery Models Opened to Biotech Startups by Eli Lilly
Eli Lilly unveiled TuneLab, an AI platform granting early-stage biotechs access to proprietary drug discovery models developed using decades of Lilly’s research data. Participating companies...
Breakthrough Alzheimer’s Vaccine ALZ-101 Initiates Phase II Clinical Trial
Alzinova secured FDA approval to advance its novel Alzheimer’s vaccine candidate ALZ-101 into Phase II clinical testing in the United States. ALZ-101 is designed to stimulate antibodies targeting...
RedC Biotech Advances Lab-Grown Universal Blood Supply Technology
RedC Biotech, founded by Dr. Ari Gargir, is developing a scalable platform to produce lab-grown, universal donor red blood cells from stem cells in large bioreactors. This innovation aims to...
New Technique Decodes RNA-Protein Interactions to Advance Molecular Biology
Researchers developed a sequencing-based methodology providing a comprehensive resource mapping human RNA-protein associations on a genome-wide scale. This novel approach elucidates the complex...
Innovative Antibody–Bottlebrush Prodrugs Enhance Targeted Cancer Therapy
Scientists at MIT have engineered antibody–bottlebrush conjugates that expand antibody-drug conjugate (ADC) payload flexibility by enabling higher drug-to-antibody ratios and inclusion of lower...
Immune System Aging Markers Identified in Early Rheumatoid Arthritis
A University of Birmingham study discovered premature immune aging signatures present during the earliest stages of rheumatoid arthritis (RA), prior to clinical diagnosis. This pivotal finding...
Novartis Bets $1.4B on Tourmaline’s Heart Drug to Challenge Cardio Giants
Novartis announced a $1.4 billion acquisition of Tourmaline Bio, securing rights to pacibekitug, a promising Phase 3-ready antibody targeting atherosclerotic cardiovascular disease. The drug aims...
Rapport’s Seizure Drug RAP-219 Surges With Strong Phase II Data
Rapport Therapeutics released compelling Phase II results for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator aimed at treating drug-resistant focal onset seizures. The trial showed...
Distinguished Biotech Veteran Harvey Berger Named Arena BioWorks CEO
Arena BioWorks, launched in 2024 with $500 million funding from high-profile billionaires, has appointed biotech veteran Harvey Berger as its new CEO. Berger reunites with co-founder Stuart...
Breakthrough in Glioblastoma: Extrachromosomal DNA Drives Tumor Evolution
An international research consortium has shed light on the role of circular extrachromosomal DNA (ecDNA) elements in the progression and treatment resistance of glioblastoma, the deadliest brain...
Lilly Opens AI Drug Discovery Platform to Biotech Startups
Eli Lilly has launched TuneLab, an AI-powered platform granting biotech firms access to Lilly’s trained drug discovery models in exchange for contributing their data to improve the system....
New Alzheimer’s Vaccine ALZ-101 Moves to Phase II After FDA Approval
Swedish biopharmaceutical company Alzinova secured FDA approval to initiate a Phase II clinical trial for ALZ-101, a vaccine candidate targeting toxic amyloid-beta oligomers implicated in...